Syon Capital LLC Invests $490,000 in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Syon Capital LLC acquired a new position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 13,556 shares of the company's stock, valued at approximately $490,000.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Huntington National Bank increased its holdings in shares of SpringWorks Therapeutics by 38.2% in the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock valued at $25,000 after acquiring an additional 192 shares during the last quarter. AlphaQuest LLC increased its stake in SpringWorks Therapeutics by 70.2% during the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after purchasing an additional 414 shares during the last quarter. Barclays PLC increased its stake in SpringWorks Therapeutics by 0.3% during the fourth quarter. Barclays PLC now owns 156,123 shares of the company's stock valued at $5,641,000 after purchasing an additional 447 shares during the last quarter. KBC Group NV raised its holdings in shares of SpringWorks Therapeutics by 59.1% during the fourth quarter. KBC Group NV now owns 2,634 shares of the company's stock worth $95,000 after purchasing an additional 978 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of SpringWorks Therapeutics by 1.7% in the 4th quarter. Legal & General Group Plc now owns 65,765 shares of the company's stock worth $2,376,000 after buying an additional 1,097 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wedbush restated an "outperform" rating and set a $81.00 price objective on shares of SpringWorks Therapeutics in a research note on Thursday, February 20th. Evercore ISI upped their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Guggenheim dropped their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Finally, HC Wainwright reissued a "buy" rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $73.20.

Insider Buying and Selling at SpringWorks Therapeutics

In other news, insider Bhavesh Ashar sold 1,016 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $61.19, for a total value of $62,169.04. Following the completion of the transaction, the insider now owns 62,053 shares in the company, valued at $3,797,023.07. This represents a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Saqib Islam sold 49,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.24, for a total transaction of $2,657,760.00. Following the transaction, the chief executive officer now directly owns 954,869 shares of the company's stock, valued at $51,792,094.56. This represents a 4.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 440,766 shares of company stock worth $24,402,956. Company insiders own 7.83% of the company's stock.

SpringWorks Therapeutics Trading Down 0.5 %

SpringWorks Therapeutics stock traded down $0.21 during trading hours on Friday, reaching $44.72. 7,805,636 shares of the company were exchanged, compared to its average volume of 1,469,383. The firm has a market cap of $3.35 billion, a price-to-earnings ratio of -12.85 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00. The stock has a 50-day moving average of $46.20 and a 200 day moving average of $40.64.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The firm had revenue of $61.55 million during the quarter, compared to analyst estimates of $60.53 million. As a group, research analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.